ZA946881B - Methods for treating gastrointestinal motility - Google Patents

Methods for treating gastrointestinal motility

Info

Publication number
ZA946881B
ZA946881B ZA946881A ZA946881A ZA946881B ZA 946881 B ZA946881 B ZA 946881B ZA 946881 A ZA946881 A ZA 946881A ZA 946881 A ZA946881 A ZA 946881A ZA 946881 B ZA946881 B ZA 946881B
Authority
ZA
South Africa
Prior art keywords
methods
gastrointestinal motility
treating gastrointestinal
gastric emptying
motility
Prior art date
Application number
ZA946881A
Other languages
English (en)
Inventor
Orville G Kolterman
Andrew A Young
Timothy J Rink
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of ZA946881B publication Critical patent/ZA946881B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
ZA946881A 1993-09-07 1994-09-07 Methods for treating gastrointestinal motility ZA946881B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11838193A 1993-09-07 1993-09-07

Publications (1)

Publication Number Publication Date
ZA946881B true ZA946881B (en) 1995-10-30

Family

ID=22378228

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA946881A ZA946881B (en) 1993-09-07 1994-09-07 Methods for treating gastrointestinal motility

Country Status (23)

Country Link
US (4) US6114304A (de)
EP (1) EP0717635B1 (de)
JP (2) JP3821839B2 (de)
KR (2) KR100429966B1 (de)
CN (1) CN1134110A (de)
AT (1) ATE197549T1 (de)
AU (1) AU7685894A (de)
BG (1) BG100463A (de)
BR (1) BR9407424A (de)
CA (1) CA2171207C (de)
CZ (1) CZ69596A3 (de)
DE (1) DE69426304T2 (de)
DK (1) DK0717635T3 (de)
ES (1) ES2154299T3 (de)
GR (1) GR3035387T3 (de)
HU (1) HUT73490A (de)
NO (1) NO960899L (de)
PT (1) PT717635E (de)
RU (1) RU2177331C2 (de)
SG (1) SG98356A1 (de)
SK (1) SK31496A3 (de)
WO (1) WO1995007098A1 (de)
ZA (1) ZA946881B (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
RU2177331C2 (ru) * 1993-09-07 2001-12-27 Амилин Фармасьютикалз, Инк. Способы регулирования моторики желудочно-кишечного тракта
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
CA2262647C (en) 1996-08-08 2007-12-04 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
DK1629849T4 (en) 1997-01-07 2017-12-04 Amylin Pharmaceuticals Llc Pharmaceutical compositions comprising exedins and agonists thereof
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
US6936584B1 (en) 1998-02-13 2005-08-30 Amylin Pharmaceuticals, Inc. Mixed amylin activity compounds
DE69943039D1 (de) * 1998-02-13 2011-01-27 Amylin Pharmaceuticals Inc Neue verbindungen mit gemischter amylin aktivität
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
EP1140145B2 (de) 1999-01-14 2019-05-15 Amylin Pharmaceuticals, LLC Neue exendin agonist formulierungen und deren verabreichung
ES2343072T3 (es) 1999-01-14 2010-07-22 Amylin Pharmaceuticals, Inc. Exendina para la supresion del glucagon.
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
EP1261282B1 (de) 2000-03-03 2013-09-25 C. R. Bard, Inc. Endoskopisches gewebeappositionsgerät mit mehreren absaugöffnungen
US7220266B2 (en) 2000-05-19 2007-05-22 C. R. Bard, Inc. Tissue capturing and suturing device and method
US6451813B1 (en) 2001-01-26 2002-09-17 R. T. Alamo Ventures I, Llc Treatment of gastroparesis in certain patient groups
JP2006510593A (ja) * 2002-09-12 2006-03-30 ザ ユニヴァーシティ オヴ シカゴ 胃内容排出及び胃不全麻痺のモニタリング及び診断
US8168233B2 (en) * 2002-10-18 2012-05-01 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
MXPA05006994A (es) * 2002-12-27 2005-10-18 Diobex Inc Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina.
EP1663289A2 (de) * 2003-08-29 2006-06-07 Amylin Pharmaceuticals, Inc. Verfahren zur behandlung oder linderung von erkrankungen und störungen im zusammenhang mit ghrelin
AU2005320351B2 (en) * 2004-02-11 2010-06-03 Amylin Pharmaceuticals, Llc Amylin family peptides and methods for making and using them
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US8172857B2 (en) 2004-08-27 2012-05-08 Davol, Inc. Endoscopic tissue apposition device and method of use
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
DE602005013811D1 (de) 2004-11-01 2009-05-20 Amylin Pharmaceuticals Inc Behandlung von fettsucht und verbundenen erkrankungen
CN101189021B (zh) 2005-03-31 2011-12-14 安米林药品公司 用于控制、预防和治疗肥胖和进食障碍的组合物和方法
WO2007104786A1 (en) 2006-03-15 2007-09-20 Novo Nordisk A/S Mixtures of amylin and insulin
WO2007112069A2 (en) * 2006-03-23 2007-10-04 Amylin Pharmaceuticals, Inc. Endothelin and endothelin receptor agonists in the treatment of metabolic diseases
US20090181890A1 (en) * 2006-03-31 2009-07-16 Amylin Pharmaceuticals , Inc. Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
EP2120985B1 (de) 2007-02-05 2012-06-27 Amylin Pharmaceuticals, Inc. FN-38 Peptide zur Verwendung bei der Behandlung Psychotischer- und Angsterkrankungen
MX2010005345A (es) * 2007-11-14 2010-08-31 Amylin Pharmaceuticals Inc Metodos para el tratamiento de la obesidad y enfermedades y trastornos relacionados con la obesidad.
RU2537181C2 (ru) 2009-03-12 2014-12-27 Нордик Байосайенс А/С Лечение диабета и метаболического синдрома
WO2010107874A2 (en) * 2009-03-17 2010-09-23 Amylin Pharmaceuticals, Inc. Methods for affecting body composition using amylin agonists
CA2797133C (en) 2010-04-27 2019-08-06 Zealand Pharma A/S Peptide conjugates of glp-1 receptor agonists and gastrin and their use
AR088636A1 (es) 2011-11-03 2014-06-25 Zealand Pharma As Conjugados peptidicos de un agonista del receptor de glp-1 y gastrina
CN104662038B (zh) 2012-07-23 2018-11-06 西兰制药公司 胰高血糖素类似物
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
EP3057984B1 (de) 2013-10-17 2018-07-11 Zealand Pharma A/S Acylierte glucagon-analoga
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
TR201902516T4 (tr) 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
CN105849122B (zh) 2013-11-06 2021-04-30 西兰制药公司 Gip-glp-1双重激动剂化合物及方法
US9656017B2 (en) 2014-06-20 2017-05-23 Howard E. Greene Infusion delivery devices and methods
EP3212218B1 (de) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip-agonisten-verbindungen und -verfahren
WO2016146739A1 (en) 2015-03-18 2016-09-22 Zealand Pharma A/S Amylin analogues
ES2763329T3 (es) 2015-04-16 2020-05-28 Zealand Pharma As Análogo de glucagón acilado
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
PE20191083A1 (es) 2016-12-09 2019-08-20 Zealand Pharma As Agonistas duales acilados de glp-1/glp-2
US10463717B2 (en) 2016-12-27 2019-11-05 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid
EP4019039B1 (de) 2017-07-27 2023-10-11 Adocia Zusammensetzungen in form einer injizierbaren wässrigen lösung, die mindestens ein humaninsulin a21g und einen prandial wirkenden glukagonsuppressor enthalten
MX2020005916A (es) 2017-12-07 2020-10-19 Adocia Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido.
WO2019115411A1 (fr) 2017-12-07 2019-06-20 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3083086A1 (fr) 2018-06-29 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
EP3740227A1 (de) 2017-12-07 2020-11-25 Adocia Zusammensetzungen in form einer injizierbaren wässrigen lösung mit amylin, einem amylin-rezeptor-agonist oder einem amylin-analogon und einer copolyaminosäure
EP3740195A1 (de) 2017-12-07 2020-11-25 Adocia Zusammensetzungen in form einer injizierbaren wässrigen lösung mit amylin, einem amylin-rezeptor-agonist oder einem amylin-analogon und einer copolyaminosäure
FR3083085B1 (fr) 2018-06-29 2020-10-02 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3084586B1 (fr) 2018-08-03 2020-11-06 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451394A (en) * 1982-10-25 1984-05-29 American Home Products Corporation Dodecapeptides preventing glucose and triglyceride assimilation
US4530838A (en) * 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
US4690486A (en) * 1985-04-29 1987-09-01 Texas Instruments Incorporated Four position interlacing apparatus
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
US5367052A (en) * 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5166192A (en) * 1989-05-09 1992-11-24 Mathias John R Treatment of motility disorders with a GnRH analog
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
US5187154A (en) * 1990-12-13 1993-02-16 Board Of Regents, The University Of Texas System Diagnosis and treatment of humans with diabetes or at risk to develop diabetes
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
AU669110B2 (en) * 1991-05-24 1996-05-30 Amylin Pharmaceuticals, Inc. Amylin and possibly insulin containing composition for the treatment of anorexia and related states
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
CA2100745C (en) * 1991-11-19 2007-07-31 Laura S. L. Gaeta Amylin agonist peptides and uses therefor
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
WO1994020116A1 (en) * 1993-03-10 1994-09-15 University Of Alabama Research Foundation Artificial primers for glycogen synthesis
RU2177331C2 (ru) * 1993-09-07 2001-12-27 Амилин Фармасьютикалз, Инк. Способы регулирования моторики желудочно-кишечного тракта
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists

Also Published As

Publication number Publication date
US6608029B1 (en) 2003-08-19
NO960899L (no) 1996-05-06
JP2004331674A (ja) 2004-11-25
EP0717635B1 (de) 2000-11-15
JPH09502443A (ja) 1997-03-11
RU2177331C2 (ru) 2001-12-27
JP3821839B2 (ja) 2006-09-13
SK31496A3 (en) 1998-06-03
US5795861A (en) 1998-08-18
BR9407424A (pt) 1996-04-09
AU7685894A (en) 1995-03-27
DE69426304T2 (de) 2001-03-15
CZ69596A3 (en) 1997-06-11
KR20040004418A (ko) 2004-01-13
GR3035387T3 (en) 2001-05-31
US7407934B2 (en) 2008-08-05
BG100463A (en) 1997-03-31
EP0717635A1 (de) 1996-06-26
ES2154299T3 (es) 2001-04-01
WO1995007098A1 (en) 1995-03-16
US6114304A (en) 2000-09-05
DE69426304D1 (de) 2000-12-21
SG98356A1 (en) 2003-09-19
CA2171207C (en) 2010-03-30
CA2171207A1 (en) 1995-03-16
US20040097415A1 (en) 2004-05-20
CN1134110A (zh) 1996-10-23
KR100391399B1 (ko) 2004-02-11
PT717635E (pt) 2001-04-30
KR100429966B1 (ko) 2004-05-04
ATE197549T1 (de) 2000-12-15
DK0717635T3 (da) 2000-12-11
HU9600558D0 (en) 1996-05-28
NO960899D0 (no) 1996-03-06
HUT73490A (en) 1996-08-28

Similar Documents

Publication Publication Date Title
ZA946881B (en) Methods for treating gastrointestinal motility
CA2262647A1 (en) Methods for regulating gastrointestinal motility
NZ504258A (en) Exendin 3 and 4 agonist compounds for the treatment of diabetes
CA2274596A1 (en) Compositions and methods for enhancing intestinal function
CY1107752T1 (el) Xρηση των εξενδινων και αγωνιστων τους για τη θεραπεια του σακχαρωδους διαβητη της κυησης
EP1618898A3 (de) Verfahren zur Regulation der Angiogenese
PL346520A1 (en) Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
NZ502610A (en) Use of lactobacillus for reduction of the fibrinogen level in blood
NZ504256A (en) Exendin 3 and 4 agonist compounds for treating diabetes
CA2257077A1 (en) Treatment of diarrhea
IL112373A0 (en) Use of interleukin-12 to prevent graft versus host disease
LT2002063A (en) Low-dose metformin and gliburide combinations for treating diabetes
WO2003000242A3 (en) Method for the treatment of lymphedema using guaifenesin
UA27035C2 (uk) Кристал білка, зшитого багатофуhкціоhальhим зшивальним агеhтом (варіаhти), пристрій, що містить кристал білка та спосіб отримаhhя аспартаму
GR3031250T3 (en) Methods of diagnosing and treating preeclampsia
CA2340320A1 (en) Use of an angiogenic factor for the treatment of microascular angiopathies
HK1047707A1 (zh) (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途
UA50761C2 (uk) Спосіб запобігання та/або лікування серцевих захворювань, фармацевтична композиція та спосіб запобігання та/або лікування серцевої недостатності та дисфункції шлуночків в організмі теплокровної тварини
WO1999059628A3 (en) Combination therapy for the treatment of tumors
WO1992018536A3 (en) Method for detecting an localizing tissues having neurokinine 1 receptors
AP2000001950A0 (en) Paroxetine maleate.
EP1417971A3 (de) Verwendung eines angiogenen Faktors zur Behandlung von mikrovaskulären Angiopathien
AU6648200A (en) Method and composition for preventing or treating adverse physiological effects associated with cardiac disease
PT979098E (pt) Metodo para o tratamento da hiperprolactinemia e de prolactinomas
ES8507552A1 (es) Un procedimiento para preparar 6-metilsulfonil-espiro-(croman-4,4'-imidazolidin)-2',5'-diona